None
Quote | Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)
Last: | $1.66 |
---|---|
Change Percent: | 0.0% |
Open: | $1.62 |
Close: | $1.66 |
High: | $1.66 |
Low: | $1.59 |
Volume: | 1,674,064 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)
2024-06-21 10:07:49 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript Lexicon Pharmaceuticals Q1 2024 Earnings Preview Seeking Alpha’s...
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and Potential Launch in Early 2025 THE WOODLANDS, Texas, June 21, 2024 (GLOBE NEWSWIR...
Message Board Posts | Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $LXRX News Article - Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpet | whytestocks | investorshangout | 04/21/2023 4:35:49 PM |
Passing 2.69. | BooDog | investorshub | 04/17/2023 1:50:06 PM |
Let's get the move on. | BooDog | investorshub | 04/14/2023 2:51:12 PM |
PUDUFA coming in a couple months. Looks | BooDog | investorshub | 03/06/2023 2:36:59 PM |
znewcar1: $LXRX 22% v1,7M c2.68 f188,725M H2.85 ML2.13=RL | znewcar1 | investorshangout | 03/03/2023 10:04:33 PM |
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and Potential Launch in Early 2025 THE WOODLANDS, Texas, June 21, 2024 (GLOBE NEWSWIR...
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP) Investigators conclude that clinical outcomes of RELIEF-DPN 1 support commencement of Lexiconȁ...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the Journal of Comparative Effectiveness Research THE WOODLANDS, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pha...